Table 4.
∆ Change in glucose-insulin status, indices of IS and β-cell function after surgery.
| Parameters | Group A (n = 10) Acromegaly without Diabetes |
Group B (n = 10) Acromegaly with Diabetes |
Wilcoxon Signed Rank Test for group A Z (P value) |
Wilcoxon Signed Rank Test for group B Z (P value) |
Man Whitney U test between Group A and Group B Chi square (p value) |
||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-op Mean ± S. D. (Mean Rank) |
Post-op Mean ± S. D. (Mean Rank) |
Delta Change Mean ± S. D. (Mean Rank) |
Pre-op Mean ± S. D. (Mean Rank) |
Post-op Mean ± S. D. (Mean Rank) |
Delta Change Mean ± S. D. (Mean Rank) |
||||
| FPG (mg/dl) | 93.6 ± 3.8 (1.00) |
85.2 ± 5.1 (6.00) |
−8.4 ± 6.7 (11.90) | 145.1 ± 49.2 (3.00) |
111.0 ± 25.1 (6.13) |
−36.7 ± 49.1 (09.10) |
−2.701 (0.007**) |
−2.191 (0.028*) | 36.000 (0.290) |
| FPI (µU/ml) | 20.8 ± 8.4 (0.000 |
8.6 ± 6.1 (5.50) |
−15.9 ± 8.56 (8.40) |
30.4 ± 23.4 (0.00) |
14.4 ± 12.0 (5.50) |
−9.6 ± 7.9 (12.60) |
−2.803 (0.005**) |
−2.803 (0.005**) | 29.000 (0.112) |
| Fasting C-peptide (ng/ml) | 4.2 ± 1.2 (1.00) |
3.1 ± 1.0 (6.00) |
−1.8 ± 1.6 (10.95) |
5.5 ± 3.9 (3.00) |
3.1 ± 1.7 (5.78) |
−1.7 ± 1.3 (10.05) |
−2.703 (0.007**) |
−2.497 (0.013**) | 45.500 (0.734) |
| HOMA-IR | 3.5 ± 1.0 (0.00) |
2.2 ± 0.7 (5.50) |
−1.3 ± 1.1 (11.60) | 4.1 ± 1.6 (6.00) |
2.5 ± 1.5 (1.00) |
−1.7 ± 1.1 (9.40) |
−2.803 (0.005**) | −2.701 (0.007**) | 39.000 (0.406) |
| HOMA-IS | 30.2 ± 7.9 (5.50) |
49.8 ± 14.1 (0.00) |
19.6 ± 13.6 (11.60) |
26.7 ± 7.6 (6.00) | 60.3 ± 50.2 (1.00) |
33.6 ± 48.5 (9.40) |
−2.803 (0.005**) | −2.70 (0.007**) | 45.000 (0.705) |
| Matsuda Index | 1.6 ± 0.5 (5.50) |
5.4 ± 3.3 (0.00) |
3.9 ± 2.9 (10.00) |
1.6 ± 1.4 (5.50) |
4.1 ± 2.8 (0.00) |
2.5 ± 2.5 (11.00) |
−2.803 (0.005**) | −2.803 (0.005**) | 33.000 (0.199) |
| HOMA-β | 213.1 ± 48.8 (4.00) |
186.2 ± 56.2 (6.50) |
−26.9 ± 72.3 (12.200 | 112.0 ± 43.9 (6.50) |
114.9 ± 32.0 (4.83) |
2.9 ± 47.4 (8.80) |
−1.172 (0.241) |
−0.153 (0.878) | 36.500 (0.307) |
| Insulinogenic index | 4.4 ± 4.5 (7.00) |
2.2 ± 1.6 (5.53) |
−2.2 ± 3.9 (8.60) |
1.6 ± 1.0 (5.33) |
1.4 ± 0.9 (5.75) |
−0.2 ± 0.8 (12.40) |
−2.090 (0.037*) | −1.173 (0.241) | 31.000 (0.151) |
| Hyperinsulinemic Euglycemic Clamp | |||||||||
| GDR (mg/kg/min) | 2.7 ± 0.9 (5.89) |
4.2 ± 1.2 (2.00) |
1.6, 1.3 (11.00) |
1.8 ± 0.6 (5.50) |
3.1 ± 1.6 (0.00) |
1.3 ± 1.3 (10.00) |
−2.599 (0.009**) | −2.805 (0.005**) | 45.000 (0.705) |
| IS (mg/kg/min/uU/ml) | 4.5 ± 2.1 (5.50) |
9.9 ± 3.9 (0.00) |
5.4,3.2 (13.90) |
4.1 ± 2.7 (6.000 |
6.3 ± 3.6 (1.00) |
2.2 ± 2.2 (7.10) |
−2.805 (0.005*) | −2.701 (0.007**) | 16.000 (0.009**) |
FPG - Fasting plasma glucose; FPI - Fasting plasma insulin; FPC - Fasting plasma c-peptide; HOMA-IR- Homeostatic model assessment of insulin resistance; HOMA-β -Homeostatic model assessment of β cell function; HOMA-IS- Homeostatic model assessment of insulin sensitivity; GDR: Glucose disposal rate; and IS- insulin sensitivity. *P < 0.05, **P < 0.01, ***P < 0.001.